Elaprase idursulfase: Phase I/II data

Top-line data from an open-label, U.S. and U.K. Phase I/II trial in about 16 Hunter Syndrome patients with CNS symptoms showed that once-monthly 1, 10 and 30 mg doses of intrathecal idursulfase were w...